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Abstract
Background: Recently, some studies indicate that interleukin (IL)-17, known as a T cell (Th17)-derived
proinflammatory cytokine, is the major mediator of tissue inflammation in inflammatory and autoimmune diseases.
Viral myocarditis (VMC) is a T cell-mediated autoimmune disease, but the role for IL-17 in VMC is not well defined.
Results: Using IL-17 monoclonal antibody (IL-17mAb)-treated VMC mice, we tested the pathogenic role of IL-17 in
the development of VMC. VMC mice were treated with monoclonal rat anti-murine IL-17 antibody (anti-IL-17) or rat
IgG2A isotype control or phosphate-buffered solution 3 days after Coxsackievirus B3 (CVB3) injection. Normal mice
without any manipulation were taken as normal control. The survival rates of mice were monitored and heart
pathology was examined histologically. IL-17, IL-6, and TNF-a mRNA of the myocardium were assessed by semi-
quantitative RT-PCR. Systemic IL-17, IL-6, and TNF-a level were measured by enzyme-linked immunosorbent assay,
and local myocardium IL-17 expression was analyzed using immunohistochemical staining. Flow cytometric analysis
was used to evaluate the frequencies of Th17 subsets in CD4
+T cells. Results showed that neutralization of IL-17
with anti-IL-17 can ameliorate clinical symptoms, defer disease course, decrease serum IL-17 level, without
declining the IL-17, IL-6 and TNF-a mRNA transcript level and serum IL-6, TNF-a level. The differentiation and
proliferation of the Th17 cells were unchanged.
Conclusions: Our data suggest that IL-17 is crucially involved in the pathogenesis of murine VMC, IL-17 inhibition
might ameliorate the myocardium inflammation after the onset of VMC.
Background
Coxsackievirus B3 (CVB3), a member of the Picorna-
viridae family, is the leading cause of viral myocarditis,
which can develop into dilated cardiomyopathy [1,2].
Both the direct viral response and immune-mediated
mechanisms have been shown to contribute to the
pathogenesis of acute injury and subsequent cardiac
remodeling [3,4]. Until now, there is no effective ther-
apy for this disease [5]. Infection of CVB3 in BALB/c
murine model can induce myocarditis with a pathologi-
cal process resembling human disease, thus this model
has been widely used for studying both the acute
infectious phase and chronic immune phase of human
viral myocarditis [6,7]. In past times, a multitude of
studies had investigated the role of the Th1 and Th2
mediated cytokine pattern present in animals with
VMC. However, it has been demonstrated that IL-23
rather than IL-12 is critical for the initiation of inflam-
matory and antuimmunity diseases [8,9]. IL-17, a cru-
cial effector cytokine specifically triggered by IL-23, has
been shown to be an essential inflammatory mediator
in other autoimmune diseases and inflammatory condi-
tions, including VMC [10-15]. Therefore, in the present
study, the IL-17 monoclonal antibody (IL-17mAb) was
given to VMC mice in order to investigate the thera-
peutic efficacy of IL-17 neutralization in VMC mouse
model. * Correspondence: wucna@yahoo.com.cn
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IL-17mAb alleviated the development of myocarditis
Results showed that IL-17mAb alleviate the severity of
myocarditis. The survival rate of IL-17mAb group mice
were significantly improved comparing with the isotype
control and PBS groups [Figure 1]. The number of mice
survived to 14 d was 8, 7, 4 and 5 for normal, IL-17mAb,
isotype control and PBS groups separately. Statistical dif-
ferences were seen when comparing the survive rate of
anti-IL-17 therapy with that of isotype control or PBS
groups (P < 0.05), There was no statistical difference of
survival rate between isotype control and PBS groups
(P> 0.05), and no statistical difference was seen between
the IL-17mAb and normal mice (P > 0.05).
IL-17mAb alleviated the severity of VMC
The value of HW/BW, pathological scores of heart sec-
tions, IOD of IL-17 expression in mice receiving IL-
17mAb were lower than those of isotype control and
PBS mice (P < 0.05), but the pathological scores and
IOD of IL-17 expression of IL-17mAb treated mice
were a little higher than normal mice (P < 0.05). There
was no significant difference of the HW/BW, the patho-
logical scores, and IOD between the isotype control and
PBS groups (Figure. 2A, B, C, D, E, P > 0.05).
IL-17mAb reduced circulating level of IL-17
To further determine whether IL-17 was involved in the
pathology of VMC, we used RT-PCR to compare the
transcriptional levels of IL-17 in heart tissue and the
related cytokines IL-6, TNF-a.T h e s ec y t o k i n e sh a v e
previously been shown to be involved in myocarditis
and may play a role in long-term immunity. Compared
with the normal group, the levels of cardiac IL-17, IL-6
and TNF-a mRNA in the IL-17mAb, isotype control
and PBS groups were elevated dramatically (P < 0.05),
but no statistical difference were seen when compared
the levels of cardiac IL-17, L-6, and TNF-a mRNA
among IL-17mAb, isotype control and PBS groups(P >
0.05, Figure 3A, B). The levels of serum IL-17 in the IL-
17 mAb, isotype control and PBS groups were higher
when compared with those in the normal mice, espe-
cially in the isotype control and PBS groups (P < 0.05,
Figure. 3C). Treating with IL-17mAb reduced the level
of total circulating IL-17, which was much lower than
those of the isotype control and PBS groups (P <0 . 0 5 )
but still higher than that of normal mice (P <0 . 0 5 ) .N o
significant difference was seen between the isotype con-
trol group and PBS group (P >0 . 0 5 ,F i g u r e .3 C ) .T h e
levels of serum IL-6 and TNF-a in the IL-17mAb, isotype
control and PBS groups also increased when compared
with those in the normal group (P <0 . 0 5 ) ,a n dt h e r e
were no significant differences among the IL-17 mAb,
isotype control and PBS groups (P > 0.05, Figure. 3D),
which imply that IL-17mAb could not reduce the level of
total circulating IL-6 and TNF-a.
IL-17mAb did not reduce percentages of CD4
+ Th17 cells
Compared with the normal group, the percentages of
CD4
+ Th17 cells in the IL-17 mAb, isotype control and
PBS groups increased markedly (P < 0.05, Figure 4).
Although the percentage of CD4
+Th17 cells in the IL-17
mAb group trended lower than that of the isotype con-
trol and PBS groups, there were no significant differ-
ences among them (P > 0.05). Th17 frequencies in the
normal, IL-17 mAb, isotype control and PBS group were
0.77 ± 0.21%, 2.41 ± 0.57%, 2.77 ± 0.78% and 2.65 ±
0.63%, respectively.
Discussion
VCM is a T cell-mediated autoimmune disease. The
classical theories suggest that Th1/Th2 cytokine balance
plays an important role in the pathogenesis of VMC.
Th17 cells have been recognized a unique CD4
+
T helper-cell (Th) subset, which is characterized by pro-
duction of IL-17 [16,17]. Emerging data suggest that
Th17 cells may play very important roles in inflamma-
tory and autoimmunity diseases, including VCM
[10-15]. Demonstration of the role of IL-17 in many
inflammatory and autoimmunity conditions further sup-
port the concept of IL-17 targeting for treatment. Signif-
icantly, recent clinical trials with short duration IL-17
antagonists’ therapy in established rheumatoid arthritis
Figure 1 Effects of anti-IL-17 cytokine therapy on survival rate.
The survival rate of IL-17mAb group mice was significantly
improved comparing with the isotype control and PBS groups (P <
0.05). No statistical difference was seen between the IL-17mAb and
normal mice (P > 0.05). Eight mice in normal group, seven mice in
IL-17mAb group, four mice in isotype control group and five mice
in PBS group survived to 14 days.
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of IL-17 in RA, and indicating that blockade of IL-17 in
human may be a valid therapeutic approach [18]. There-
fore, in the present study, the IL-17mAb was given to
BALB/c mice after CVB3 infection to investigate
whether IL-17 antibody treatment can influence the dif-
ferentiation and proliferation of Th17 cells after the
onset of VMC, thus to be may be a valid therapeutic
approach for VMC.
Our results showed that IL-17mAb improved the sur-
vival rate of treated VMC mice. Consistently, histologi-
cal analysis of heart sections revealed that IL-17 mAb
attenuate the severity of myocarditis, verified by the
decreased HW/BW, a relief of myocardial inflammation,
and improved pathological score of heart sections. All
the above data indicate that IL-17mAb could rescue
mice from myocarditis caused by CVB3 infection, indi-
cating a protective effect of IL-17mAb. To gain insight
into the mechanism of action during IL-17 neutraliza-
tion, Th17 cell frequency, IL-17, IL-6, TNF-a mRNA,
serum levels of IL-17 and IL-6 were measured in all ani-
mals at the time they were sacrificed. IL-17mAb reduced
the circulating level of IL-17, but neither IL-17/IL-6/
TNF-a mRNA nor circulating IL-6/TNF-a decreased.
TNF-a was secreted primarily by myocytes and macro-
phages after injury as well as Th1 and Th17 cells
[19,20]. Previous studies have demonstrated that car-
diac-specific expression of TNF-a result in myocardial
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Figure 2 Evaluation of the severity of VMC. A, The value of heart weight/body weight (HW/BW) in different groups. The value for each group
was 0.42 ± 0.07%, 0.41 ± 0.04%, 0.50 ± 0.05% and 0.52 ± 0.04%, respectively. B, The pathological scores in different groups. Scores for each
group were 0.0 ± 0.0, 0.4 ± 0.5, 3.0 ± 0.0 and 2.8 ± 0.4 respectively. Each point represents an individual mouse. C, Representative of
histopathological images in heart tissue (H&E, original magnification×400), a: Normal group; b: IL-17mAb group; c: Isotype control group; d: PBS
group. D, Representative of IL-17 Immunohistochemistry images in heart tissue (dark brown granules, original magnification×400). a: Normal
group; b: IL-17mAb group; c: Isotype control group; d: PBS group. E, Morphometric quantitation of IL-17 protein expression in myocardium. IOD
in different groups were 36.04 ± 4.17, 106.41 ± 12.10, 2500.95 ± 65.83 and 2029.63 ± 69.21 respectively. Representative myocardial sections from
normal (n = 8), IL-17mAb (n = 7), isotype control (n = 4) and PBS (n = 5) mice. △P > 0.05, *P < 0.05. Data are mean ± SD.
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Page 3 of 7inflammation, cardiac hypertrophy, progressive dilatation
and increased apoptosis, which leads to heart failure and
death [21]. A role for TNF-a in VMC is supported by
the recent findings that lack of TNF-a induction is a
major factor in female resistance to VMC, exogenous
TNF-a also makes normally CVB3 myocarditis-resistant
female mice susceptible [22]. IL-6, produced by cells of
the innate immune system such as dendritic cells (DCs),
monocytes, macrophages, mast cells, B cells, and subsets
of activated T cells, including Th17 cells, is clearly a
pleiotropic cytokine with multiple effects. As IL-17 can
induce the release of many cytokines, such as IL-6,
TNF-a and IL-1b, from monocytes, epithelial cells, and
fibroblasts et al, when VMC mice were given IL-17 anti-
body, although circulating IL-17 decreased, the secretion
of IL-6 and TNF-a from monocytes et al did not
decrease. As an independent subset of T helper cells,
Th17 cells were established by the identification of dif-
ferentiation factors and transcription factors that are
unique to Th17 cells. The differentiation factors (TGF-b
plus IL-6 or IL-21) [23-25], the growth and stabilization
factor (IL-23), and the transcription factors (STAT3,
RORgt, and RORa) involve in the development of Th17
cells [26,27]. We have previously demonstrated that
Th17 cells differentiate and proliferate from day 7 after
CVB3 infection [28], with IL-23, together with other
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Figure 3 IL-17, IL-6 and TNF-a mRNA transcription in VMC myocardium and protein level in the serum.A .R e p r e s e n t a t i v ei m a g e s
showing semiquantitative RT-PCR for IL-17, IL-6 and TNF-a transcription. 1. Normal group; 2. IL-17mAb group; 3. Isotype control group; 4. PBS
group. B, Densitometric quantitation of the PCR bands showed that, among the IL-17mAb, isotype control and PBS groups, the mRNA
expression did not differ with each other; C, The levels of serum IL-17 in different groups, measured by ELISA. The IL-17 protein levels were 11.81
± 2.66, 22.56 ± 3.68, 33.63 ± 5.50, 33.68 ± 6.13 pg/ml in normal, IL-17mAb, Isotype control and PBS group respectively. D, The levels of serum IL-
6 and TNF-a in different group, measured by ELISA. The IL-6 levels were 23.15 ± 8.59, 71.28.50 ± 15.80, 77.81 ± 6.54, 78.18 ± 6.26 pg/ml, and the
TNF-a levels were 27.80 ± 4.52, 64.24 ± 6.71, 67.89 ± 5.25, 63.45 ± 2.71 pg/ml respectively. Normal group (n = 8), IL17mAb (n = 7), isotype
contro(n = 4), and PBS group(n = 5).*P < 0.05, △P > 0.05. Data are mean ± SD.
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Figure 4 The percentages of Th17 cells investigated by flow cytometry in each group of spleens. Th17 subsets were gated with CD4
+ IL-
17
+/CD4
+ cells. The percentage of positive cells was shown in each panel. Numbers in upper right quadrants represented an average number of
each group. a: Normal group; b: IL-17mAb group; c: Isotype control group; d: PBS group.
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Page 4 of 7cytokines such as IL-6 and TGF-b expression increased
(unpublished observations). In present study, IL-17mAb
was gave 3 days after CVB3 infection, in addition with
the less but ongoing inflammation, the cytokines pro-
posed to be the differentiation factors for Th17 cells still
exist, as a result, there was no influence on the differen-
tiation and proliferation of Th17 cells.
Since there was no complete reduction of the VMC
symptoms and the inflammation of myocardium, some
causes may elucidate for this. First, as we did not quan-
tify the neutralization of cytokine antibody biological
activity, the dose of given IL-17mAb might not be able
antagonism with circulating IL-17 in vivo completely.
Second, the biological activity, affinity and/or potency of
IL-17 antibody in vivo are uncertain. What more, other
factors may compensate for the insufficient effect of IL-
17. There is a little difference with the previous one,
which may be explained by the internal of time and the
total amount of antibody given [29].
Conclusions
IL-17 plays a central role in the development of VMC.
Neutralization of IL-17 with a monoclonal antibody
starting after onset of VMC result in an attenuated
VMC course and ameliorate clinical symptoms. How-
ever, several questions remain unset. Since there was no
complete reduction of the VMC symptoms, other fac-
tors seem to compensate for the temporary deficiency of
IL-17 and provide efficient effector cells recruitment,
secondary loss of response to IL-17 inhibition may
result from the induction of other pathways and repla-
cing the initial IL-17 contribution. Thus, the role of
IL-17 inhibition in the treatment of inflammatory condi-
tions remains to be defined.
Methods
Mice
S p e c i f i cp a t h o g e n - f r e em a l eB A L B / cm i c e( 6 - w e e k - o l d )
were purchased from Shanghai Laboratory Animal Cen-
tre, Chinese Academy of Sciences, Shanghai, China
(Certificate No.0062353-SCXK (SH) 2007-0005). Ethical
approval was obtained from the Guangxi Medical Uni-
versity Animal Ethics Committee before the start of the
study. All animals were housed in a pathogen-free
mouse room in an experimental animal center (Guangxi
Medical University), fed with normal mouse chow and
tap water ad libitum.
CVB3 Titration in Cells
Heart-passaged CVB3 (Nancy strain, from Institute of
immunology of Guangxi Medical University) was propa-
gated in Hep-2 cells, cultured in monolayer and stored
in a -80°C freezer. The supernatant from infected cell
cultures was collected, and viral titers were determined
in 96-well plates by the end-point dilution method.
Briefly, 10-fold serial dilutions (1:10 to 1:10
-10)o fp h o s -
phate-buffered solution (PBS, Solarbio Science & Tech-
nology Co, Ltd, Beijing, China) were prepared, and the
50% tissue culture infectious dose (TCID50)t i t e rw a s
determined by the cytopathic effects visible after 72 h.
The TCID50 assay result for Hep-2 cells was 1×10
-7.
IL-17 neutralization
Mice were intraperitoneally injection (i.p) with 0.1 ml of
PBS containing approximately 100TCID50 of the virus.
The day when mice were i.p was defined as day 0.
Followed by injection, the mice were injected intraperi-
toneally with 100 μg IL-17 monoclonal antibody (n = 8,
R & DS y s t e m s ,I n c .M i n n e a p o l i s ,M N .M A B 4 2 1 ,
IL-17mAb group), or 100 μg isotype control immuno-
globulin (Ig) G2AAb (n = 8, R&D, Systems, Inc. Minnea-
p o l i s ,M N .M A B 0 0 6 ,i s o t y p ec o n t r o lg r o u p ) ,o rP B S
(n = 8, PBS group) on day 4, 7 and day 10. In addition,
left uninfected and without any intervention mice were
assigned as the normal control (n = 8, normal group).
All surviving animals were sacrificed on day 14 after
CVB3 infection, the values of the heart weight/body
weight (HW/BW) were recorded.
Histopathology
The ventricular tissues of the hearts were cut longitud-
inally, fixed in 10% phosphate-buffered formalin,
embedded in paraffin. The myocardial tissues were cut
into 5-μm sections and stained with hematoxylin &
eosin to determine the level of inflammation. Stained
sections were viewed using light microscopy(Nikon
Eclipse E800 Microscope, Kawasaki, Kanagawa, Japan),
a n dg r a d e di nab l i n d e dm a n n e rb yt w op a t h o l o g i s t s
based on the following semi-quantitative scale: 0, no
inflammatory infiltrates; 1, small foci of inflammatory
cells between myocytes or inflammatory cells surround-
ing individual myocytes; 2, larger foci of 100 inflamma-
tory cells or involving at least 30 myocytes; 3, 10% of a
myocardial cross-section involved; and 4, 30% of a myo-
cardial cross-section involved [30].
Immunohistochemistry
Immunohistochemical staining was performed by the
streptavidin-biotin complex method. Rabbit polyclonal
antibodies against mouse IL-17 (Santa Cruz Biotechnol-
ogy, CA) at a 1:100 dilution were used as primary anti-
bodies. The sections were washed and stained using the
streptavidin-biotin complex kit (Boster, Wuhan, China)
according to the manufacturer’s manual. The procedures
were as follows: after the sections were rehydrated,
endogenous peroxidase activity was blocked with 3%
hydrogen peroxide for 10 min at room temperature.
After washing with distilled water, the sections were
Fan et al. Virology Journal 2011, 8:17
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utes at room temperature and then in the primary anti-
body for 24 h at 4°C. Next, the sections were washed
with PBS and then incubated with the streptavidin-
biotin complex for 20 minutes. Finally, the sections
were developed with 3,3-diaminobenzidine (Boster,
Wuhan, China) and observed under a light microscope
(Eclipse E800, Nikon, Japan). Non-immune goat serum
was used instead of primary antibody as a control. IL-17
deposition in the cytoplasm and cytomembrane were
categorized semi-quantitatively according to the extent
and intensity of staining using Image Pro Plus Version
6.0 (Media Cybernetics, Bethesda, MD). Two pathology
experts randomly selected 5 fields from each slice
for blinded scoring and analysis by integrated optical
density (IOD).
Lymphocyte preparation
Spleens from the four groups of mice were harvested
aseptically. After mincing, the cell suspension was
pipetted rapidly with a sterile Pasteur pipette into 3 ml
of RPMI 1640(Gibco, USA), filtered through nylon mesh
to eliminate debris, and centrifuged at 1000 rpm for
5 min. The cells were washed twice with RPMI 1640.
The lymphocyte fractions of these samples were
obtained by Ficoll Paque (Solarbio Science &Technol-
ogy) gradient centrifugation, the suspension was layered
carefully over 3 ml of Ficoll Paque and centrifuged at
2000 rpm for 15 min. Lymphocytes were maintained in
a 24-well flat-bottom tissue culture plate with RPMI
1640 supplemented with 10% fetal calf serum (Gibco,
USA) at 37°C in a humidified atmosphere with 5% CO2.
Intracellular cytokine flow cytometry
Cytokine-producing cells were determined by intracellu-
lar staining using phycoerythrin-conjugated anti-mouse
IL-17 (PE-IL-17) and phycoerythrin cyanine-5-conju-
gated anti-mouse CD4 (PE-Cy5-CD4). Briefly, cells were
stimulated with phorbol myristate acetate (25 ng/ml,
Sigma-Aldrich), ionomycin(1 μg/ml, Sigma-Aldrich), and
GolgiPlug (1 μl/10
6 cells, BD Biosciences) for 4 hours.
Cells were fixed in 4% paraformaldehyde, permeabilized
with 0.1% saponin, stained with fluorescent antibodies
against IL-17 and CD4, and analyzed on a FACSCalibur
flow cytometer (BD Biosciences). CellQuest software
(BD Biosciences) was used for data acquisition.
Semi-quantitative RT-PCR detection of IL-17, IL-6, TNF-a
mRNA
Total mRNA was extracted from homogenized heart tis-
sues by using of the TRIZOL Reagent
® (Invitrogen,
USA), and then used to synthesize cDNA with an RT
Kit (Ferma, USA). Reverse-transcription PCR (RT-PCR)
was performed with first-strand cDNA synthesized with
1 μg of total RNA and oligo d(T)18 primers according
to the manufacturer’s instructions. The primers for the
RT-PCR assays for IL-17A, IL-6 and TNF-a were
designed by Primer Premier 5.0 (Table 1). Mouse b-
actin, a reference gene, was used to normalize each sam-
ple and each gene. Prepared cDNA was used for PCR
amplification with the above primers under the follow-
ing conditions: pre-heating at 94°C for 3 min, denatur-
ing at 94°C for 30 sec, annealing at at 64.9°C (IL-17) or
62°C (IL-6) or 62.5°C (TNF-a) for 30 sec, and extension
at 72°C for 60 sec. The reaction repeated for 35 cycles
followed by incubation at 72°C for 10 min. PCR pro-
ducts were analyzed by electrophoresis on a 2% agarose
gel containing 0.5 mg/ml ethidium bromide. The result-
ing bands were observed and photographed under ultra-
violet light, and then measured using the Digital Gel
Imaging Analyst (Nikon 990-Doc 1000, USA). Density
was determined for each sample PCR product, including
the positive control. Background density was subtracted
from each band and the relative values of IL-17, IL-6
and TNF-a mRNA were calculated using b-actin mRNA
as a standard. PCR products was sequenced by Songon
Biotech Co., Ltd (Shanghai, China), and blasted in the
NCBI Blast bank.
Cytokine assay
Blood were collected via retro-orbital bleeding and serum
was separated. The amounts of IL-17 in the blood plasma
were detected using the Quantikine Mouse IL-17 Immu-
noassay (R&D Systems, Minneapolis, MN, USA) and the
amounts of IL-6, TNF-a were detected by Quantikine
Mouse IL-6, TNF-a Immunoassay (Shanghai ExCell Biol-
ogy Inc. China). The minimum detectable doses of IL-17,
IL-6 and TNF-a were 5, 15.6 and 15.6 pg/ml respectively.
No cross-reactivity was observed in detection. All samples
were measured in triplicate.
Statistical analysis
All data were expressed as mean ± SD. One-way ANOVA
and the q tests were used for comparison among four
Table 1 Sequences of primers for RT-PCR
Molecule Sequence (5’-3’) length
IL-6[GenBank:16193] sense:
5’CACAGAAGGAGTGGCTAAGGACCA3’
antisense:
5’ACGCACTAGGTTTGCCGAGTAGA3’
103 bp
IL-17[GenBank:16171] sense: 5’GTCAATGCGGAGGGAAAG3’
antisense: 5’CACGAAGCAGTTTGGGAC 3’
349 bp
TNF-a
GenBank:21926]
sense: 5’CACTGGAGCCTCGAATGTC3’
antisense:
5’CAGGGAAGAATCTGGAAAGGT3’
128 bp
b-actin
[GenBank:11461]
sense: 5’CCAGCCTTCCTTCTTGGGTAT3’
antisense:
5’TTGGCATAGAGGTCTTTACGG 3’
102 bp
Fan et al. Virology Journal 2011, 8:17
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Page 6 of 7groups. All data were analyzed with SPSS 16.0 for Win-
dows. A significant difference was defined as P <0 . 0 5 .
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